Short-term efficacy and safety of camrelizumab-based treatment in refractory or metastatic esophageal squamous cell carcinoma.

IF 0.9 4区医学 Q4 ONCOLOGY

Indian journal of cancer Pub Date : 2024-10-01 Epub Date: 2025-02-17 DOI:10.4103/ijc.IJC_1275_20

Yuan Yuan, Qingliang Meng, Xiaowu Li, Youwei Zhang, Sanyuan Sun

{"title":"Short-term efficacy and safety of camrelizumab-based treatment in refractory or metastatic esophageal squamous cell carcinoma.","authors":"Yuan Yuan, Qingliang Meng, Xiaowu Li, Youwei Zhang, Sanyuan Sun","doi":"10.4103/ijc.IJC_1275_20","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to evaluate the short-term efficacy and safety of camrelizumab in combination with apatinib in the treatment of refractory or metastatic esophageal squamous cell carcinoma (ESCC).Methods: We retrospectively reviewed the medical records of 30 patients with refractory or metastatic ESCC treated with camrelizumab in combination with apatinib at a single institution. The short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria. The safety was evaluated by the Common Terminology Criteria for Adverse Events criteria.Results: Among all the 30 patients, the overall response rate and disease control rate were 8/30 (27%) and 19/30 (63%), respectively. Complete response was achieved in 0/30 (0%), partial response in 8/30 (27%), stable disease in 11/30 (36%), and progressive disease in 11/30 (37%). The median progression-free survival was 3.7 (95% confidence interval: 2.48 - 3.88) months and the median overall survival was not reached.Conclusion: Our study has shown that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favorable clinical safety.","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"710-713"},"PeriodicalIF":0.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijc.IJC_1275_20","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to evaluate the short-term efficacy and safety of camrelizumab in combination with apatinib in the treatment of refractory or metastatic esophageal squamous cell carcinoma (ESCC).

Methods: We retrospectively reviewed the medical records of 30 patients with refractory or metastatic ESCC treated with camrelizumab in combination with apatinib at a single institution. The short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria. The safety was evaluated by the Common Terminology Criteria for Adverse Events criteria.

Results: Among all the 30 patients, the overall response rate and disease control rate were 8/30 (27%) and 19/30 (63%), respectively. Complete response was achieved in 0/30 (0%), partial response in 8/30 (27%), stable disease in 11/30 (36%), and progressive disease in 11/30 (37%). The median progression-free survival was 3.7 (95% confidence interval: 2.48 - 3.88) months and the median overall survival was not reached.

Conclusion: Our study has shown that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favorable clinical safety.

查看原文本刊更多论文

基于camremizumab治疗难治性或转移性食管鳞状细胞癌的短期疗效和安全性。

背景：本研究的目的是评估camrelizumab联合阿帕替尼治疗难治性或转移性食管鳞状细胞癌（ESCC）的短期疗效和安全性。方法：我们回顾性回顾了30例难治性或转移性ESCC患者在同一医院接受camrelizumab联合阿帕替尼治疗的病历。根据实体瘤应答评价标准评价短期疗效。安全性根据不良事件标准通用术语标准进行评估。结果：30例患者中，总有效率为8/30(27%)，疾病控制率为19/30（63%）。0/30患者完全缓解（0%），8/30患者部分缓解（27%），11/30患者病情稳定（36%），11/30患者病情进展（37%）。中位无进展生存期为3.7个月（95%可信区间：2.48 - 3.88），中位总生存期未达到。结论：我们的研究表明，camrelizumab联合阿帕替尼对于难治性或转移性ESCC患者是一种很有希望的治疗方法。该联合治疗有效率高，临床安全性好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian journal of cancer Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of ontological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India.